Literature DB >> 19364638

Glycosylated hemoglobin and the risk of death and cardiovascular mortality in the elderly.

M Chonchol1, R Katz, L F Fried, M J Sarnak, D S Siscovick, A B Newman, E S Strotmeyer, A Bertoni, M G Shlipak.   

Abstract

BACKGROUND AND AIMS: Glycosylated hemoglobin (HbA(1c)) has been associated with incident cardiovascular disease (CVD), but the findings are inconsistent. We tested the hypothesis that HbA(1c) may be associated with an increased risk of death and cardiovascular mortality in older adults. METHODS AND
RESULTS: We evaluated the association between HbA(1c) with all-cause and cardiovascular mortality in 810 participants without a history of diabetes in a sub-study of the Cardiovascular Health Study (CHS), a community cohort study of individuals > or =65 years of age. Glycosylated hemoglobin was measured at baseline and all-cause and cardiovascular mortality was assessed during the follow-up period. The relation between baseline HbA(1c) and death was evaluated with multivariate Cox proportional hazards regression models. After a median follow-up of 14.2 years, 416 deaths were observed. The crude incidence rates of all-cause mortality across HbA(1c) groups were: 4.4% per year, 4.3% per year and 4.6% per year for tertile 1 (< or =5.6%), tertile 2 (5.61-6.20%) and tertile 3 (> or =6.21%), respectively. In unadjusted and fully adjusted analyses, baseline HbA(1c) was not associated with all-cause mortality and cardiovascular mortality (hazard ratio: 1.16 [95% confidence interval 0.91-1.47] and hazard ratio: 1.31 [95% confidence interval 0.90-1.93], respectively for the highest HbA(1c) tertile compared with the lowest).
CONCLUSION: These results suggest that HbA(1c) does not significantly predict all-cause and cardiovascular mortality in non-diabetic community-dwelling older adults. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364638      PMCID: PMC2888268          DOI: 10.1016/j.numecd.2009.02.007

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  25 in total

Review 1.  Standardization of HbA1c measurements--a consensus statement.

Authors:  S M Marshall; J H Barth
Journal:  Diabet Med       Date:  2000-01       Impact factor: 4.359

2.  The Cardiovascular Health Study: design and rationale.

Authors:  L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman
Journal:  Ann Epidemiol       Date:  1991-02       Impact factor: 3.797

3.  Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus.

Authors:  R J Koenig; C M Peterson; R L Jones; C Saudek; M Lehrman; A Cerami
Journal:  N Engl J Med       Date:  1976-08-19       Impact factor: 91.245

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. The Cardiovascular Health Study Collaborative Research Group.

Authors:  B M Psaty; M Lee; P J Savage; G H Rutan; P S German; M Lyles
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

6.  Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk.

Authors:  Kay-Tee Khaw; Nicholas Wareham; Sheila Bingham; Robert Luben; Ailsa Welch; Nicholas Day
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

7.  Hemoglobin A1c level and future cardiovascular events among women.

Authors:  Gavin J Blake; Aruna D Pradhan; JoAnn E Manson; G Rhys Williams; Julie Buring; Paul M Ridker; Robert J Glynn
Journal:  Arch Intern Med       Date:  2004-04-12

Review 8.  Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease.

Authors:  Susan J Zieman; David A Kass
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors:  Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

Review 10.  Non enzymatic glycated proteins in the blood and cardiovascular disease.

Authors:  G Misciagna; G De Michele; M Trevisan
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

View more
  15 in total

1.  Low hemoglobin A1c and risk of all-cause mortality among US adults without diabetes.

Authors:  April P Carson; Caroline S Fox; Darren K McGuire; Emily B Levitan; Martin Laclaustra; Devin M Mann; Paul Muntner
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-10-05

2.  Glycated Hemoglobin Level and Mortality in a Nondiabetic Population with CKD.

Authors:  Claire Trivin; Marie Metzger; Jean-Philippe Haymann; Jean-Jacques Boffa; Martin Flamant; François Vrtovsnik; Pascal Houillier; Benedicte Stengel; Eric Thervet
Journal:  Clin J Am Soc Nephrol       Date:  2015-05-15       Impact factor: 8.237

3.  Metabolic Clusters and Outcomes in Older Adults: The Cardiovascular Health Study.

Authors:  Kenneth J Mukamal; David S Siscovick; Ian H de Boer; Joachim H Ix; Jorge R Kizer; Luc Djoussé; Annette L Fitzpatrick; Russell P Tracy; Edward J Boyko; Steven E Kahn; Alice M Arnold
Journal:  J Am Geriatr Soc       Date:  2018-02       Impact factor: 5.562

4.  Biochemical risk indices, including plasma homocysteine, that prospectively predict mortality in older British people: the National Diet and Nutrition Survey of People Aged 65 Years and Over.

Authors:  Christopher J Bates; Mohammed A Mansoor; Kristina D Pentieva; Mark Hamer; Gita D Mishra
Journal:  Br J Nutr       Date:  2010-04-19       Impact factor: 3.718

5.  Prediction and classification of cardiovascular disease risk in older adults with diabetes.

Authors:  K J Mukamal; J R Kizer; L Djoussé; J H Ix; S Zieman; D S Siscovick; C T Sibley; R P Tracy; A M Arnold
Journal:  Diabetologia       Date:  2012-11-10       Impact factor: 10.122

6.  Association between visit-to-visit variability of glycemic indices and lipid profile and the incidence of coronary heart disease in adults with type 2 diabetes.

Authors:  Fatemeh Moosaie; Marjan Mouodi; Ali Sheikhy; Aida Fallahzadeh; Niloofar Deravi; Soghra Rabizadeh; Seyede Marzie Fatemi Abhari; Alipasha Meysamie; Fatemeh Dehghani Firouzabadi; Manouchehr Nakhjavani; Alireza Esteghamati
Journal:  J Diabetes Metab Disord       Date:  2021-11-02

7.  Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction.

Authors:  Harald Jörn Schneider; Henri Wallaschofski; Henry Völzke; Marcello Ricardo Paulista Markus; Marcus Doerr; Stephan B Felix; Matthias Nauck; Nele Friedrich
Journal:  PLoS One       Date:  2012-03-16       Impact factor: 3.240

8.  Association of hemoglobin A1c and glycated albumin with carotid atherosclerosis in community-dwelling Japanese subjects: the Hisayama Study.

Authors:  Naoko Mukai; Toshiharu Ninomiya; Jun Hata; Yoichiro Hirakawa; Fumie Ikeda; Masayo Fukuhara; Taeko Hotta; Masafumi Koga; Udai Nakamura; Dongchon Kang; Takanari Kitazono; Yutaka Kiyohara
Journal:  Cardiovasc Diabetol       Date:  2015-06-24       Impact factor: 9.951

9.  Glycaemic markers and all-cause mortality in older adults with and without diabetes: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Mary R Rooney; Olive Tang; James S Pankow; Elizabeth Selvin
Journal:  Diabetologia       Date:  2020-09-29       Impact factor: 10.122

10.  Hemoglobin A1c and arterial and ventricular stiffness in older adults.

Authors:  Susan J Zieman; Aruna Kamineni; Joachim H Ix; Joshua Barzilay; Luc Djoussé; Jorge R Kizer; Mary L Biggs; Ian H de Boer; Michel Chonchol; John S Gottdiener; Elizabeth Selvin; Anne B Newman; Lewis H Kuller; David S Siscovick; Kenneth J Mukamal
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.